- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00799526
Transplant of Epithelium Conjunctival Human Autologous Cultivated ex Vivo in Amniotic Membrane for the Treatment of Symblepharon
November 28, 2008 updated by: Federal University of São Paulo
The purpose of this study is to investigate the safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface in patients with symblepharon.
Study Overview
Status
Unknown
Conditions
Detailed Description
10 patients will be included from 16 to 90 years with presence of symblepharon, what have been already subjected to proceedings of reconstruction of the ocular surface without success and to present conjunctival healthy.
In the place of biopsy and after the surgery of the patient one will be applied ointment with antibiotic and corticoid to minimize the inflammatory effects.
The fragments will be transported even it laboratory of Molecular Biology of the advanced Centre of Ocular Surface where it will be prosecuted by means of technique sterile under laminating flow.
The conjunctival epithelias cells will be put on the amniotic membrane compartments of the plate of culture where the appropriate ways will be added.
After 2 weeks the membranes colonized with epithelium conjunctival they will be subjected to the coloration and the cloth will be used for the surgery of reconstruction of the ocular surface.
It will be carried out first us an evaluation ophthalmologic complete weekly, 2 months and then fortnightly up to the sixth month post-operative.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 90 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with ocular surface disorders, e.g. symblepharon
- Indications for surgery will be the presence of ocular surface symptoms in the affected eye, loss of visual acuity from visual axis obscuration or irregular astigmatism, or cosmesis.
- Only one eye of a patient will be eligible for study entry.
- Patients who are adult males and females who are aged 16 or older, and are considered mentally sound
- Patients who are willing to undergo long-term follow-up, as outlined in this protocol
- Patients who have signed an informed consent form that has been approved by the SNEC Ethics Committee.
Exclusion Criteria:
- Patients less than 16 years of age
- Patients who are incapable, either by law or of mental state, of giving consent in their own right
- Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol
- Patients who are pregnant or breastfeeding
- Patients with a history of drug allergy
- Patients who have received an investigational drug within 28 days preceding surgery
- Patients with intraocular pressure over 21 mmHg or history of ocular hypertension or glaucoma
- Patients who are documented to be steroid responders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Ex Vivo Transplantation
Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
|
Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reconstruction of Ocular surface in patients with symblepharon
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Re - reconstruction of Ocular surface in patients with symblepharon
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
November 1, 2008
Study Completion (Anticipated)
November 1, 2010
Study Registration Dates
First Submitted
November 28, 2008
First Submitted That Met QC Criteria
November 28, 2008
First Posted (Estimate)
December 1, 2008
Study Record Updates
Last Update Posted (Estimate)
December 1, 2008
Last Update Submitted That Met QC Criteria
November 28, 2008
Last Verified
November 1, 2008
More Information
Terms related to this study
Other Study ID Numbers
- 1075/08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symblepharon
-
National Taiwan University HospitalTerminatedSymblepharon | Limbal InsufficiencyTaiwan
-
Federal University of São PauloCompletedDry Eye | Transplantation | Ocular Surface Disease | SymblepharonBrazil
Clinical Trials on Autologous Ex Vivo Conjunctival for Symblepharon Transplantation
-
University Hospital, BordeauxCompleted
-
InCor Heart InstituteFundação de Amparo à Pesquisa do Estado de São PauloUnknownRespiratory Tract DiseasesBrazil
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States
-
Medgenics Medical Israel Ltd.TerminatedAnemia | End Stage Renal Disease
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Juvenile Diabetes...CompletedType 1 Diabetes MellitusUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnemia | Weight Loss | Thrombocytopenia | Fever | Chronic Lymphocytic Leukemia | Lymphadenopathy | Prolymphocytic Leukemia | Richter Syndrome | Cancer Fatigue | Recurrent Chronic Lymphocytic Leukemia | Lymphocytosis | Infectious Disorder | Night Sweats | Secondary Malignant NeoplasmUnited States
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Shanghai Institute of Materia Medica, Chinese Academy of SciencesRecruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaNot yet recruitingLung Transplant SurgeryItaly
-
University of FloridaBeat Childhood Cancer Research ConsortiumActive, not recruitingNeuroblastoma | Diffuse Intrinsic Pontine GliomaUnited States
-
University of ManchesterManchester University NHS Foundation Trust; Great Ormond Street Hospital for... and other collaboratorsActive, not recruitingMucopolysaccharidosis IIUnited Kingdom